| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.21 | 2e-08 |
| mRNA | ABT-737 | CTRPv2 | pan-cancer | AAC | 0.16 | 6e-05 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.15 | 7e-05 |
| mRNA | OSI-930 | GDSC1000 | pan-cancer | AAC | 0.14 | 0.0001 |
| mRNA | Sunitinib | GDSC1000 | pan-cancer | AAC | 0.22 | 0.0001 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0001 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.23 | 0.0002 |
| mRNA | I-BET-762 | GDSC1000 | pan-cancer | AAC | 0.1 | 0.0004 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0005 |
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0006 |